ARO PNPLA3
Alternative Names: ARO-JNJ1; ARO-PNPLA3; JNJ-0795; JNJ-75220795Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Arrowhead Pharmaceuticals
- Developer Arrowhead Pharmaceuticals; Johnson & Johnson Innovative Medicine
- Class Hepatoprotectants; Small interfering RNA
- Mechanism of Action Adiponutrin expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fatty liver; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Fatty liver in Japan (SC, Injection)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in USA (SC, Injection)
- 28 May 2024 No recent reports of development identified for phase-I development in Fatty liver in USA (SC, Injection)